Avutometinib/Defactinib and Gemcitabine/Nab-Paclitaxel Combination in First-Line Metastatic Pancreatic Ductal Adenocarcinoma: Initial Safety and Efficacy of Phase 1b/2 Study (RAMP 205)
Avutometinib/Defactinib and Gemcitabine/Nab-Paclitaxel Combination in First-Line Metastatic Pancreatic Ductal Adenocarcinoma: Initial Safety and Efficacy of Phase 1b/2 Study (RAMP 205)
This website uses cookies to improve the site and user experience. By continuing to browse this site, you agree to accept our use of cookies. For more information, please review our Privacy Policy.
